Get Permission Kumar, Kumar, Vaiphei, and Kumar: Primary hepatic neuroendocrine tumor with sarcoid like granulomas: A case report


Introduction

Neuroendocrine tumor (NET) constitutes 1-2% of all gastrointestinal tumors. The liver is involved frequently as a metastatic focus.1 Primary hepatic neuroendocrine tumor (PHNET) is a rare entity comprising 0.3% of all neuroendocrine tumors.2 Edmondson reported the first case in 1958.2 Since these tumors constitute only a small proportion of NET, the approach to diagnosis and management is not well established. With the surgical approach as the primary modality of treatment, overall, 5 and 10 years survival rates are 78% and 73% respectively.2, 3 Tumors coexisting with granulomas are occasionally noted with malignancies in the lymph nodes draining the tumor or within the primary tumor itself. Tumor-related sarcoid like granuloma requires the presence of compact non-caseating granuloma without clinical features of systemic sarcoidosis.4 The tumor-related sarcoid reaction occurs in only 4% of carcinomas and its association with a NET has been reported only once in a pancreatic NET.5 We report a case of PHNET in a 63-year male who presented with various comorbidities who was incidentally detected with a liver space-occupying lesion (SOL).

Case Report

A 63-year male was on follow-up for essential hypertension, Type 2 diabetes mellitus, and subclinical hypothyroidism, presented with acute problems related to acute coronary ischemia and heart failure. On routine examination, he was found to have mild hepatomegaly with no palpable spleen and ascites. There was no significant family history. His routine laboratory investigation profiles of haemogram, renal, and liver function tests were within normal limits. Serum amylase 48 U/L, Serum gastrin 12 pgM, CEA 1.88 ng/ml, AFP 1.21 ng/ml, TSH 6.57 mIU/L, T3 1.15 μg/dl, T4 8.87 μg/dl, GH 0.38 ng/ml, RBS 170 mg/dl, FBS- 103 mg/dl, IGF1 257.6 ng/ml, Basal insulin 7.84, C Peptide- 15.94 ng/ml and HIAA (24 hour urinary)- 2mg/hr. Contrast enhanced CT scan of the abdomen revealed a well-defined exophytic mass in the liver measuring 4.9 ×5.1 cm involving segment 6. Subsequently patient underwent 68Ga DOTANOC PET/CT scanning revealed a somatostatin receptor-expressing well-defined lesion measuring 5.1 x 5.0 cm in segment 6 (SUV MAX 19). No other abnormal somatostatin receptor-expressing focus in the body were noted. A diagnosis of either a primary or a metastatic neuroendocrine tumor was made and the patient was taken up for surgery. A non-anatomical wedge resection of the tumor was done. A detailed exploration of the abdominal cavity to look for a primary focus did not reveal any other lesion or mass. The post-operative period was uneventful and on follow-up, the patient has no evidence of recurrence radiologically and clinically to date.

The wedge resected specimen measured 6x4x1.5 cm and the capsular aspect showed a greyish white nodule. On serial slicing the tumor was sub-capsular in location, measuring 5.2x4x4 cm. Cut surface showed a brownish tumor with areas of congestion giving a variegated appearance with internal septations and areas of hemorrhages. Surrounding liver parenchyma was unremarkable. On histology, the tumor was observed to be poorly circumscribed. Tumor cells showed organoid, trabeculae, and cord patterns of arrangement with intervening delicate capillary network and hyalinised fibrous septae. The tumor cells were polygonal in shape with monomorphic round nuclei with stippled chromatin, inconspicuous nucleoli, and scant to moderate pale eosinophilic cytoplasm. Mitosis was 4 per 10 high power field (hpf). The advancing edge of the tumor showed multiple well-formed compact epithelioid cell granulomas with multinucleated Langhan type of giant cells. The surrounding liver parenchyma showed maintained lobular architecture, portal tracts with minimal lymphomononuclear cell infiltrate. Immunohistochemistry showed tumor cells positive for cytokeratin (Cell Marque, 1:300), synaptophysin (Cell Marque, 1:300), Chromogranin A (Dako, 1:200), and CD56 (Dako, 1: 80), however negative for HepPar 1 (Dako, 1: 300). The Ki 67 index was 10% in the highest proliferative areas.

Figure 1

A): Maximum intensity projection (MIP) images show focal tracer uptake in the liver; B) and C): Transaxial fused 68Ga DOTANOC PET/CT and corresponding axial CT images respectively showing somatostatin receptor-expressing lesion in segment VI of the liver

https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/3bb43472-1897-42cd-8e0b-9a45431dd058/image/3c6f5caf-38da-4c7e-beaa-c676dfc0c876-uimage.png

Figure 2

A): Gross specimen shows well-circumscribed fleshy and soft to firm tumor with variegated appearance and areas of hemorrhage; B): On histology, the tumor is poorly circumscribed and is arranged in organoid and trabeculae; C): The tumorcells are relatively monomorphic with round nuclei, stippled chromatin, inconspicuous nucleoli, and scant to moderate eosinophilic cytoplasm; D): Surrounding hepatic parenchyma shows compact epithelioid cell granulomas, multinucleated giant cells, and fibrosis

https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/3bb43472-1897-42cd-8e0b-9a45431dd058/image/f5e675f5-9919-402b-b6c0-61a2c25416a2-uimage.png

Figure 3

A): Immunohistochemistry show tumor positive for cytokeratin, chromogranin; B): and synaptophysin; C): D): Ki 67 index shows nearly 10% proliferative index

https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/3bb43472-1897-42cd-8e0b-9a45431dd058/image/f24db201-9e43-4c88-afc0-49995a960e9a-uimage.png

Discussion

PHNET is a very rare tumor with less than 200 cases reported to date.6 Rarity could be explained by the fact NETs arising from neuro-ectodermal cells, which migrate from the neural crest during embryogenesis are not found in the liver routinely.7 Various hypotheses have been postulated to explain the pathogenesis of PHNETs, one of the possibilities is that they originate from ectopic pancreatic or adrenal tissues within the liver.8, 9 Another postulation is the chronic inflammation in the biliary system may initiate intestinal metaplasia, which predisposes to the development of neuroendocrine tumors.7 According to previous literature, PHNETs are more common in women in the 4th and 5th decades of life.3 These tumor are slow-growing and non-functional though rarely they may present with carcinoid syndrome10 and jaundice due to mass effect.11 Right lobe involvement has been reported more frequently and is often solitary (76.6%).3 Close differential diagnosis of these tumors remains other more common liver lesions like hydatid cyst, hepatocellular carcinoma, cholangiocarcinoma, and other metastatic carcinomas. Serum level of chromogranin A and 24-hour urine HIAA (5- hydroxyl indoleacetic acid) show promising sensitivity and specificity in diagnosing NET. CgA can be used for monitoring carcinoma recurrence. Serum markers like CEA, CA19–9, and AFP are not specific for PHNECs 12.

Radiological investigations like USG, CT, and MRI are of low sensitivity imaging modality as PHNETs are hypervascular tumor like metastatic NETs to the liver.10 68Ga DOTA peptide PET/CT is a highly useful imaging modality in the diagnosis and staging of NETs with a sensitivity and specificity of 92% and 98% respectively.13

Grossly, NETs are mostly solitary, circumscribed with a soft consistency, and may show necrosis. Histologically, PHNETs show an insular, acinar, trabecular, nested, or mixed pattern of growth. The cells show round nuclei with characteristic salt and pepper chromatin. The intense cytoplasmic granularity as seen in gut NETs is not found in hepatic primaries and would suggest metastasis from the occult primary. Even if morphological features suggest neuroendocrine carcinoma, hepatocellular carcinoma needs to be excluded as the growth patterns overlap. The diagnosis can be confirmed on immunohistochemistry as a neuroendocrine tumor is positive for synaptophysin, CD 56, chromogranin, and cytokeratins, which are however negative for hepatocytic markers like arginase and hepPar1. On the basis of proliferative activity, NETs are graded as G1 (< 2 mitosis/2 mm2 or ki-67 proliferation index <3%), G2 (2-20 mitosis/2 mm2 or a Ki-67 index of 3-20%) or G3 (>20 mitosis/2 mm2 or Ki-67 index >20%). Hepatic NETs can be WHO grade G1 or G2, G3 NETs have not been reported in the liver yet.14

Surgical resection of the tumor with negative margins is the preferred treatment modality as up to 85% of tumors are resectable.11 5 year survival after surgery is as good as 74-78%.15 For unresectable tumors, liver transplantation and TACE (transcatheter arterial chemoembolization) are the alternative modalities.11

The relationship between sarcoidosis/sarcoid-like reaction and the solid malignant tumor is less frequent with most commonly described in lung adenocarcinoma.16 Hematological malignancies like non- Hodgkin’s lymphoma and Hodgkin’s lymphoma are mainly associated with sarcoidosis/sarcoid-like reaction. In nearly 76% of cases, sarcoidosis precedes the diagnosis of neoplasm. However, individuals without any clinical signs of systemic sarcoidosis, regional lymph nodes draining malignant tumor, the primary tumor itself, and even non-regional tissues may show compact non-caseating epithelioid cell granulomas. The sarcoid-like reaction occurs with an average frequency of 4% in carcinoma, 7% in non-Hodgkin's lymphoma, and 14% in Hodgkin's disease. The mechanism for sarcoid like granulomas represents T-cells mediated immune response to the tumor antigens.5, 16

Conclusion

PHNET is a rare tumor with vague clinical presentation and radiological features. Diagnosis of a PHNET requires a combination of a negative abdominal survey at the time of the operative procedure, pathologic evaluation of specimen, and a negative imaging workup for extrahepatic NET in both the pre-and postoperative settings. Surgery with negative margins is the preferred treatment modality. Given that the recurrence rate is high despite complete surgical resection (19.8%), close follow-up is of paramount importance.

Source of Funding

None.

Conflict of Interest

None.

References

1 

IM Modlin A Sandor An analysis of 8305 cases of carcinoid tumorsCancer199779481329

2 

H Edmonson Tumor of the liver and intrahepatic bile ductAtlas Tumor Pathol19587251059

3 

CW Lin CH Lai CC Hsu CT Hsu PM Hsieh KC Hung Primary hepatic carcinoid tumor: a case report and review of the literatureCases J20092190

4 

H Brincker Interpretation of Granulomatous Lesions in MalignancyActa Oncol1992311859

5 

M Mastroroberto S Berardi L Fraticelli P Pianta G Ercolani A Cancellieri Sarcoidosis and Sarcoid-Like Reaction Associated with Pancreatic Malignancy: Are You Able to Read a RiddleJ Pancreas (Online)20121344547

6 

B Geramizadeh A Kashkooe SA Malekhosseini Liver Metastasis of Gastrointestinal Neuroendocrine Tumors: A Single Center ExperienceHepat Mon2016165e37293

7 

C Hsueh XD Tan F Gonzalez-Crussi Primary hepatic neuroendocrine carcinoma in a child. Morphologic, immunocytochemical, and molecular biologic studiesCancer199371826605

8 

LI Alpert FG Zak S Werthamer JF Bochetto Cholangiocarcinoma: a clinicopathologic study of five cases with ultrastructural observationsHum Pathol19745670928

9 

G Gravante NC DeLiguori J Overton TM Manzia G Orlando Primary carcinoids of the liver: a review of symptoms, diagnosis, and treatmentsDig Surg20082553648

10 

LX Wang K Liu GW Lin T Jiang Primary hepatic neuroendocrine tumors: comparing CT and MRI features with pathologyCancer Imaging201515113

11 

MR Deluzio AL Barbieri G Israel S Emre Two cases of primary hepatic neuroendocrine tumors and a review of the current literatureAnn Hepatol20171646219

12 

K Yang YS Cheng JJ Yang X Jiang JX Guo Primary hepatic neuroendocrine tumors: multi-modal imaging features with pathological correlationsCancer Imaging20171712010.1186/s40644-017-0120-x

13 

V Ambrosini D Campana P Tomassetti S Fanti 68Ga-labelled peptides for diagnosis of gastroenteropancreatic NETEur J Nucl Med Mol Imaging20123915260

14 

ID Nagtegaal RD Odze D Klimstra V Paradis M Rugge P Schirmacher WHO Classification of Tumours Editorial Board. The 2019 WHO classification of tumors of the digestive systemHistopathology20207621828

15 

CD Knox CD Anderson LW Lamps RB Adkins CW Pinson Long-term survival after resection for primary hepatic carcinoid tumorAnn Surg Oncol2003101011715

16 

H Brincker Sarcoid reactions in malignant tumorsCancer Treat Rev198613314756



jats-html.xsl


This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

  • Article highlights
  • Article tables
  • Article images

Article History

Received : 14-07-2022

Accepted : 21-07-2022


View Article

PDF File   Full Text Article


Copyright permission

Get article permission for commercial use

Downlaod

PDF File   XML File   ePub File


Digital Object Identifier (DOI)

Article DOI

https://doi.org/ 10.18231/j.ijpo.2022.071


Article Metrics






Article Access statistics

Viewed: 789

PDF Downloaded: 192